文献速递眼底病与葡萄膜炎

澳大利亚原住民与非原住民糖尿病视网膜病变患病率:系统综述与Meta分析

Prevalence of Diabetic Retinopathy in Indigenous and Non-Indigenous Australians: A Systematic Review and Meta-analysis.
PubMed 文献 · Ophthalmology · 2022-08-02

该系统综述与Meta分析纳入15项研究共8219名参与者,比较澳大利亚原住民与非原住民糖尿病患者的糖尿病视网膜病变(DR)患病率。未调整分析中两组DR患病率无显著差异(原住民30.2% vs 非原住民23.7%,P=0.17);调整年龄和质量后原住民DR患病率更高(P<0.01),患病率比值点估计为1.72至2.58。原住民亚组糖尿病黄斑水肿(8.7% vs 2.7%,P=0.02)和视力威胁性DR(8.6% vs 3.0%,P=0.03)患病率更高,增殖性DR无显著差异(2.5% vs 0.8%,P=0.07)。

要点

  • 未调整Meta分析中,原住民与非原住民DR患病率无显著差异(30.2% vs 23.7%,P=0.17)。
  • 调整年龄和质量后,原住民DR患病率更高(P<0.01),患病率比值点估计1.72至2.58。
  • 原住民亚组DME(8.7% vs 2.7%,P=0.02)和VTDR(8.6% vs 3.0%,P=0.03)患病率更高,增殖性DR无显著差异(2.5% vs 0.8%,P=0.07)。

核心结论

  • 原住民研究的方法学质量评分较低,提示研究实践的系统性差异可能导致疾病负担被低估。
  • 调整年龄和质量后,原住民亚组DR患病率更高,这与既往一项使用未调整合并估计报告相反结果的综述形成对比。
  • 未来探索原住民社区DR负担的流行病学工作应致力于解决本综述所识别的方法学缺陷。

研究设计与样本

  • 本研究为系统综述与Meta分析,遵循Joanna Briggs Institute关于患病率研究系统综述的指导(PROSPERO ID: CRD42022259048)。
  • 检索Medline (Ovid)、EMBASE和Web of Science至2021年10月,纳入报告澳大利亚原住民与非原住民糖尿病患者DR患病率的研究。
  • 由两名独立评审者使用9条目质量评估工具进行质量评估,采用双反正弦变换和随机效应模型进行Meta分析与Meta回归,比较原住民与非原住民亚组。
  • 共纳入15项研究,8219名参与者。

主要发现

  • 原住民亚组质量评估工具评分低于非原住民亚组(平均分50% vs 72%,P=0.04)。
  • 未调整Meta分析中,原住民亚组DR患病率(30.2%;95%CI 24.9-35.7)与非原住民亚组(23.7%;95%CI 16.8-31.4)无显著差异(P=0.17)。
  • 调整年龄和质量后,原住民亚组DR患病率更高(P<0.01),患病率比值点估计随Meta回归模型不同为1.72至2.58。
  • 原住民亚组糖尿病黄斑水肿患病率更高(8.7% vs 2.7%,P=0.02),视力威胁性DR患病率更高(8.6% vs 3.0%,P=0.03)。
  • 增殖性DR患病率在原住民亚组与非原住民亚组间无显著差异(2.5% vs 0.8%,P=0.07)。

局限性

  • 原住民研究在质量评估工具上得分较低(平均分50% vs 72%,P=0.04),提示研究实践的系统性差异可能导致疾病负担被低估。
  • 未来流行病学工作应致力于解决本综述所识别的方法学缺陷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC: This systematic review and meta-analysis summarizes evidence relating to the prevalence of diabetic retinopathy (DR) among Indigenous and non-Indigenous Australians. CLINICAL RELEVANCE: Indigenous Australians suffer disproportionately from diabetes-related complications. Exploring ethnic variation in disease is important for equitable distribution of resources and may lead to identification of ethnic-specific modifiable risk factors. Existing DR prevalence studies comparing Indigenous and non-Indigenous Australians have shown conflicting results. METHODS: This study was conducted following Joanna Briggs Institute guidance on systematic reviews of prevalence studies (PROSPERO ID: CRD42022259048). We performed searches of Medline (Ovid), EMBASE, and Web of Science until October 2021, using a strategy designed by an information specialist. We included studies reporting DR prevalence among diabetic patients in Indigenous and non-Indigenous Australian populations. Two independent reviewers performed quality assessments using a 9-item appraisal tool. Meta-analysis and meta-regression were performed using double arcsine transformation and a random-effects model comparing Indigenous and non-Indigenous subgroups. RESULTS: Fifteen studies with 8219 participants met criteria for inclusion. The Indigenous subgroup scored lower on the appraisal tool than the non-Indigenous subgroup (mean score 50% vs. 72%, P = 0.04). In the unadjusted meta-analysis, DR prevalence in the Indigenous subgroup (30.2%; 95% confidence interval [CI], 24.9-35.7) did not differ significantly (P = 0.17) from the non-Indigenous subgroup (23.7%; 95% CI, 16.8-31.4). After adjusting for age and quality, DR prevalence was higher in the Indigenous subgroup (P < 0.01), with prevalence ratio point estimates ranging from 1.72 to 2.58, depending on the meta-regression model. For the secondary outcomes, prevalence estimates were higher in the Indigenous subgroup for diabetic macular edema (DME) (8.7% vs. 2.7%, P = 0.02) and vision-threatening DR (VTDR) (8.6% vs. 3.0%, P = 0.03) but not for proliferative DR (2.5% vs. 0.8%, P = 0.07). CONCLUSIONS: Indigenous studies scored lower for methodological quality, raising the possibility that systematic differences in research practices may be leading to underestimation of disease burden. After adjusting for age and quality, we found a higher DR prevalence in the Indigenous subgroup. This contrasts with a previous review that reported the opposite finding of lower DR prevalence using unadjusted pooled estimates. Future epidemiological work exploring DR burden in Indigenous communities should aim to address methodological weaknesses identified by this review.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Chia MA, Taylor JR, Stuart KV, et al. Prevalence of Diabetic Retinopathy in Indigenous and Non-Indigenous Australians: A Systematic Review and Meta-analysis. Ophthalmology. 2022. PMID: 35931223. doi:10.1016/j.ophtha.2022.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。